SELLAS Life Sciences Group Inc

Research SELLAS Life Sciences Group Inc (SLS) on Bullrun: market cap USD 2.87B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSLS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.87B
• Financial periodFY2025
• Net income-USD 26.86M

Valuation Snapshot

latest market cap is USD 2.87B.

About SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.

Frequently asked questions

What is SELLAS Life Sciences Group Inc's market cap?

SELLAS Life Sciences Group Inc's market capitalization is USD 2.87B.

What does SELLAS Life Sciences Group Inc do?

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.